Meghna Chowdary is the Senior Vice President of Commercial Strategy at ArriVent Biopharma and brings more than 15 years of commercialization experience in large and small biopharma companies. Most recently, she was Vice President of Competitive and Strategic Assessments at Olema Oncology and built analytical and strategic planning capabilities to guide the advancement of the company’s pipeline. Prior to Olema, Ms. Chowdary was Vice President of Commercial Operations & Analytics at Portola Pharmaceuticals, where she supported the full commercial launch execution of Andexxa in the U.S. and in Europe that led to the company’s acquisition by Alexion in July 2020. Ms. Chowdary led Strategic Insights & Analytics at Relypsa and shaped the Veltassa global launch planning efforts. Earlier in her career, Ms. Chowdary was at Genentech for 10 years and held positions of increasing responsibility in the business operations organization. Ms. Chowdary received a B.S. from Stanford University and an MBA from the Wharton School of the University of Pennsylvania.